Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of Hepatitis B virus (HBV) expression
    Patent number: 8642752
    Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Michael L. McCaleb, Hong Zhang
  • Modulation of glucagon receptor expression
    Patent number: 8642753
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie, Robert McKay, Sanjay Bhanot
  • MODULATION OF ALPHA SYNUCLEIN EXPRESSION
    Publication number: 20140005252
    Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
    Type: Application
    Filed: November 17, 2011
    Publication date: January 2, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Jyothi Mallajosyula
  • COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
    Publication number: 20130281684
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: March 7, 2013
    Publication date: October 24, 2013
    Inventor: Susan M. Freier
  • MODULATION OF FACTOR 11 EXPRESSION
    Publication number: 20130274308
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: October 8, 2012
    Publication date: October 17, 2013
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
  • Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
    Patent number: 8546350
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: October 1, 2013
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Modulation of SMRT expression
    Patent number: 8541387
    Abstract: Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and/or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 24, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay K. Pandey, Sanjay Bhanot, Eric G. Marcusson, Susan M. Freier
  • MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
    Publication number: 20130237585
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 19, 2011
    Publication date: September 12, 2013
    Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Modulation of STAT 6 expression
    Patent number: 8518904
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 27, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: William R. Shanahan, Jr., Susan M. Freier, Kenneth W. Dobie
  • Modulation of HIF1? and HIF2? expression
    Patent number: 8513400
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 20, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier
  • Antisense modulation of fibroblast growth factor receptor 4 expression
    Patent number: 8486904
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 4 (FGFR4). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 4. Methods of using these compounds for modulation of fibroblast growth factor receptor 4 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 4 are provided.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: July 16, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Xing-Xian Yu, Susan M. Freier, Ravi Jain
  • Modulation of stat5 expression
    Patent number: 8476421
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: July 2, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, James G. Karras
  • Compositions and their uses directed to huntingtin
    Patent number: 8415465
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: April 9, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Compositions and their uses directed to gemin genes
    Patent number: 8409856
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of a Gemin Gene. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: April 2, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Susan M. Freier
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20130046008
    Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
    Type: Application
    Filed: February 8, 2011
    Publication date: February 21, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
  • SELECTIVE REDUCTION OF ALLELIC VARIANTS
    Publication number: 20130046007
    Abstract: Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).
    Type: Application
    Filed: February 8, 2011
    Publication date: February 21, 2013
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION
    Publication number: 20130035370
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Application
    Filed: August 3, 2012
    Publication date: February 7, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke
  • MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
    Publication number: 20130035366
    Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
    Type: Application
    Filed: April 20, 2012
    Publication date: February 7, 2013
    Inventors: Eric E. Swayze, Susan M. Freier, Michael L. McCaleb
  • Modulation of factor 11 expression
    Patent number: 8334372
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 18, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
  • Antisense modulation of apolipoprotein B-expression
    Patent number: RE44760
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: February 11, 2014
    Assignee: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier